Clinical and genetic characteristics of hereditary pancreatitis in EuropeNathan Howes, John P. Neoptolemos, Markus M. Lerch et al.|Clinical Gastroenterology and Hepatology|2004Cited by 615
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, John P. Neoptolemos, Paul Silcocks et al.|The Lancet Oncology|2014Cited by 374
Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitisDavid C. Whitcomb, Narcis Zarnescu, Lidiya Orlichenko et al.|Nature Genetics|2012Cited by 360
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 TrialWilliam Greenhalf, Markus W. Büchler, Paula Ghaneh et al.|JNCI Journal of the National Cancer Institute|2013Cited by 333
Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of diseaseFelicity Liew, Claudia Efstathiou, Sara Fontanella et al.|Nature Immunology|2024Cited by 91